N/A
N=31
Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status
Obesity · Metabolic Syndrome · Hyperuricemia
Bottom Line
View on ClinicalTrials.gov: NCT01931527 ↗Enrolled (actual)
31
Serious AEs
0.0%
Results posted
May 2015
Primary outcome: Primary: Percent Increase in Insulin-stimulated Glucose Uptake — 231; 162; NA; 156 % incr. in insulin-mediated gluc. uptake
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Rasburicase (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Washington University School of Medicine
- Primary completion
- Jun 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Increase in Insulin-stimulated Glucose Uptake |
231; 162; NA; 156 | — |
| SECONDARY The Effect of Reducing Uric Acid on Oxidative Status |
1.0; 0.68; NA; 0.96 | — |
| SECONDARY Baseline Carbonylated Protein Ratio |
929; 680 | — |
| SECONDARY AFTER Rasburicase Carbonylated Protein Ratio |
1085 | — |
| SECONDARY Baseline Plasma TRAP |
1.11; 1.31 | — |
| SECONDARY AFTER Rasburicase Plasma TRAP |
0.71 | — |
| SECONDARY Baseline Plasma FRAP |
1.03; 1.39 | — |
| SECONDARY AFTER Rasburicase Plasma FRAP (Fe⁺² · Lˉ¹) |
0.42 | — |
Summary
The purpose of this study is to learn more about what is the effect of uric acid on oxidative stress and on the way the body metabolizes sugar in obese people. Understanding this may lead to better diseases such as diabetes.
Eligibility Criteria
Inclusion Criteria
- obese (BMI 30-45 kg/m²);
- serum UA concentration either ≥5 mg/dL or ≤4.0 mg/dL (297 µmol/L)],
Exclusion Criteria
- renal dysfunction (serum creatinine >1.5 mg/dL);
- pregnancy or lactating;
- take urate-lowering agents, thiazide diuretics, prednisone or medications containing aspirin or other salicylates;
- history of xanthinuria, type 2 diabetes or other significant organ system dysfunction;
- have G6PD deficiency;
- use hormone-replacement or oral-contraceptive therapy;
- smoke tobacco;
- anemic (Hb <10 g/dl)
Data sourced from ClinicalTrials.gov (NCT01931527). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.